To optimize the potential of our drug candidates we explore various collaboration opportunities to build value and create returns for our investors while bringing meaningful treatments to patients with cancer. Our current collaborations are outlined below. 


BeiGene, Ltd. – Zandelisib Clinical Collaboration

In October 2018, we announced a clinical collaboration with BeiGene, Ltd. to evaluate the safety and efficacy of zandelisib (ME-401) in combination with BeiGene’s zanubrutinib, an investigational inhibitor of Bruton’s tyrosine kinase (“BTK”), for the treatment of patients with B-cell malignancies. Study costs will be shared equally by the parties, and we will supply zandelisib and BeiGene will supply zanubrutinib. We retain full commercial rights for zandelisib and BeiGene retains full commercial rights for zanubrutinib.

Helsinn Healthcare SA – Pracinostat Worldwide License

In August 2016, we entered into an exclusive worldwide license, development, manufacturing and commercialization agreement with Helsinn Healthcare SA, for pracinostat in acute myeloid leukemia, myelodysplastic syndrome and other potential indications. Under the agreement, Helsinn holds a worldwide exclusive license to develop, manufacture and commercialize pracinostat, and is primarily responsible for funding its global development and commercialization. Pursuant to the agreement, we received payments of $20.0 million and we are eligible to receive up to $444 million in potential regulatory and sales-based milestones, along with royalty payments on the net sales of pracinostat, which, in the U.S., are tiered and begin in the mid-teens.

Kyowa Hakko Kirin Co., Ltd. – ME-401 Japan License Agreement

In November 2018, we entered into a license, development and commercialization agreement with Kyowa Hakko Kirin Co., Ltd. (“KHK”), granting KHK exclusive rights to develop and commercialize zandelisib in Japan; we retain all other rights to zandelisib. Under the terms of the license agreement, we received a $10 million upfront payment, and we are eligible to receive additional development and commercialization milestones up to $87.5 million as well as tiered double-digit sales royalties extending into the mid-teens.

To learn more about business development with MEI, please contact our Business Development department